Somatic BRCA2 bi-allelic loss in the primary prostate cancer was associated to objective response to PARPi in a sporadic CRPC patient

<span class="paragraphSection">Recent next generation sequencing (NGS) studies conducted in primary tumours and metastatic castration-resistant prostate cancer (mCRPC) have identified a prevalence of germline and somatic defects in DNA repair genes higher than expected, particularly in the <span style="font-style:italic;">BRCA2</span> gene [<a href="#mdx067-B1" class="reflinks">1</a>]. Germline mutations and somatic defects identified in the metastases of mCRPC patients have been associated with the response to the PARP inhibitor (PARPi) olaparib and carboplatin [<a href="#mdx067-B2" class="reflinks">2</a>, <a href="#mdx067-B3" class="reflinks">3</a>]. Here we report the remarkable radiologic and biochemical response to the PARPi veliparib in a patient found to harbour a somatic <span style="font-style:italic;">BRCA2</span> bi-allelic (homozygous) loss in his primary tumour.</span>

http://ift.tt/2qS5nDk